



Lyrica® CR (pregabalin) – First-time generic

- On April 13, 2021, [Novadoz/MSN Pharmaceuticals](#) and [Alvogen](#) launched [AB-rated](#) generic versions of Pfizer's [Lyrica CR \(pregabalin\)](#) extended-release tablets.
- [Apotex](#), [Mylan/Viatris](#) and [Sun](#) received FDA approval of AB-rated generic versions of Lyrica CR on April 13, 2021. Launch dates for these generic products are pending.
- Lyrica CR is approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.
- Pregabalin is available generically as an immediate-release [capsule](#) and [oral solution](#).
- Pregabalin immediate-release capsules and oral solution have the same indications as Lyrica CR, as well as additional indications for the treatment of partial-onset seizures, fibromyalgia and neuropathic pain associated with spinal cord injury.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.